Literature DB >> 26371064

HIV-1 group O infection in Cameroon from 2006 to 2013: Prevalence, genetic diversity, evolution and public health challenges.

Christian Julian Villabona-Arenas1, Jenny Domyeum2, Fatima Mouacha3, Christelle Butel4, Eric Delaporte5, Martine Peeters6, Eitel Mpoudi-Ngole7, Avelin Fobang Aghokeng8.   

Abstract

The human immunodeficiency virus, HIV, is characterized by a tremendously high genetic diversity, leading to the currently known circulating HIV types, groups, subtypes, and recombinant forms. HIV-1 group O is one of the most diverse forms of HIV-1 and has been so far related to Cameroon or individuals originating from Cameroon. In this study, we investigated in Cameroon, the evolution of this viral group from 2006 to 2013, in terms of prevalence, genetic diversity and public health implications. Our results confirmed the predominance of HIV-1 group M (98.5%), a very low prevalence (<0.02%) for HIV-1 group N and P, and HIV-2 in this country. HIV-1 group O was found at around 0.6% (95% confidence interval: 0.4-0.8%), indicating that the frequency of this virus in Cameroon has remained stable over the last decades. However, we found an extensive high genetic diversity within this HIV-1 group, that resulted from previous steady increase on the effective number of HIV-1 group O infections through time, and the current distribution of the circulating viral strains still does not allow classification as subtypes. The frequency of dual infections with HIV-1 group M and group O was 0.8% (95% confidence interval: 0.6-1.0%), but we found no recombinant forms in co-infected patients. Natural resistance to integrase inhibitors was not identified, although we found several mutations considered as natural polymorphisms. Our study shows that infections with HIV-1 group O can be adequately managed in countries where the virus circulates, but this complex virus still represents a challenge for diagnostics and monitoring strategies.
Copyright © 2015. Published by Elsevier B.V.

Entities:  

Keywords:  Cameroon; Dual infections; Genetic diversity; HIV-1 group O; Prevalence; Resistance

Mesh:

Year:  2015        PMID: 26371064      PMCID: PMC4680975          DOI: 10.1016/j.meegid.2015.09.006

Source DB:  PubMed          Journal:  Infect Genet Evol        ISSN: 1567-1348            Impact factor:   3.342


  39 in total

1.  TREE-PUZZLE: maximum likelihood phylogenetic analysis using quartets and parallel computing.

Authors:  Heiko A Schmidt; Korbinian Strimmer; Martin Vingron; Arndt von Haeseler
Journal:  Bioinformatics       Date:  2002-03       Impact factor: 6.937

2.  Biological and genetic characteristics of HIV infections in Cameroon reveals dual group M and O infections and a correlation between SI-inducing phenotype of the predominant CRF02_AG variant and disease stage.

Authors:  Laurence Vergne; Anke Bourgeois; Eitel Mpoudi-Ngole; Rose Mougnutou; Josephine Mbuagbaw; Florian Liegeois; Christian Laurent; Christelle Butel; Léopold Zekeng; Eric Delaporte; Martine Peeters
Journal:  Virology       Date:  2003-06-05       Impact factor: 3.616

3.  Increased taxon sampling greatly reduces phylogenetic error.

Authors:  Derrick J Zwickl; David M Hillis
Journal:  Syst Biol       Date:  2002-08       Impact factor: 15.683

4.  MUSCLE: multiple sequence alignment with high accuracy and high throughput.

Authors:  Robert C Edgar
Journal:  Nucleic Acids Res       Date:  2004-03-19       Impact factor: 16.971

5.  Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses.

Authors:  D Descamps; G Collin; F Letourneur; C Apetrei; F Damond; I Loussert-Ajaka; F Simon; S Saragosti; F Brun-Vézinet
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

6.  HIV-1 group O infection in the USA.

Authors:  K Gould; L Britvan; J Dryjanski
Journal:  Lancet       Date:  1996-09-07       Impact factor: 79.321

7.  Geographical distribution of HIV-1 group O viruses in Africa.

Authors:  M Peeters; A Gueye; S Mboup; F Bibollet-Ruche; E Ekaza; C Mulanga; R Ouedrago; R Gandji; P Mpele; G Dibanga; B Koumare; M Saidou; E Esu-Williams; J P Lombart; W Badombena; N Luo; M Vanden Haesevelde; E Delaporte
Journal:  AIDS       Date:  1997-03-15       Impact factor: 4.177

8.  Human immunodeficiency virus type 1 intergroup (M/O) recombination in cameroon.

Authors:  J Takehisa; L Zekeng; E Ido; Y Yamaguchi-Kabata; I Mboudjeka; Y Harada; T Miura; L Kaptu; M Hayami
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

9.  A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon.

Authors:  L G Gürtler; P H Hauser; J Eberle; A von Brunn; S Knapp; L Zekeng; J M Tsague; L Kaptue
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

10.  Isolation and partial characterization of an unusual human immunodeficiency retrovirus from two persons of west-central African origin.

Authors:  R De Leys; B Vanderborght; M Vanden Haesevelde; L Heyndrickx; A van Geel; C Wauters; R Bernaerts; E Saman; P Nijs; B Willems
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

View more
  5 in total

1.  Novel Time-Resolved Fluorescence Europium Nanoparticle Immunoassay for Detection of Human Immunodeficiency Virus-1 Group O Viruses Using Microplate and Microchip Platforms.

Authors:  Mohan Kumar Haleyur Giri Setty; Jikun Liu; Prerna Mahtani; Panhe Zhang; Bingchen Du; Viswanath Ragupathy; Krishnakumar Devadas; Indira K Hewlett
Journal:  AIDS Res Hum Retroviruses       Date:  2016-03-15       Impact factor: 2.205

2.  Field evaluation of an open and polyvalent universal HIV-1/SIVcpz/SIVgor quantitative RT-PCR assay for HIV-1 viral load monitoring in comparison to Abbott RealTime HIV-1 in Cameroon.

Authors:  Emilande Guichet; Avelin Aghokeng; Sabrina Eymard-Duvernay; Nicole Vidal; Ahidjo Ayouba; Eitel Mpoudi Ngole; Eric Delaporte; Laura Ciaffi; Martine Peeters
Journal:  J Virol Methods       Date:  2016-09-05       Impact factor: 2.014

3.  Virologic Failure and Human Immunodeficiency Virus Drug Resistance in Rural Cameroon With Regard to the UNAIDS 90-90-90 Treatment Targets.

Authors:  Charlotte Boullé; Emilande Guichet; Charles Kouanfack; Avelin Aghokeng; Benjamin Onambany; Catherine Massama Ikaka; Emile Ngock; Landry Tsoumsta; Philippe Msellati; Eitel Mpoudi-Ngolé; Martine Peeters; Eric Delaporte; Christian Laurent
Journal:  Open Forum Infect Dis       Date:  2016-12-20       Impact factor: 3.835

4.  A cheap and open HIV viral load technique applicable in routine analysis in a resource limited setting with a wide HIV genetic diversity.

Authors:  Elodie Téclaire Ngo-Malabo; Paul Alain Ngoupo T; Martin Zekeng; Valérie Ngono; Laure Ngono; Serge Alain Sadeuh-Mba; Richard Njouom; Anfumbom Kfutwah
Journal:  Virol J       Date:  2017-11-14       Impact factor: 4.099

5.  Prevention and treatment of SHIVAD8 infection in rhesus macaques by a potent d-peptide HIV entry inhibitor.

Authors:  Yoshiaki Nishimura; J Nicholas Francis; Olivia K Donau; Eric Jesteadt; Reza Sadjadpour; Amanda R Smith; Michael S Seaman; Brett D Welch; Malcolm A Martin; Michael S Kay
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-20       Impact factor: 11.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.